Formulations And Penetration Tests In Vitro Transdermal Patch Aspirin Using A Combination Of Eudragit Polymers RL 100 And Eudragit Rs 100 With Enhancer Variations

Feb 27, 2025 by ADMIN 163 views

**Formulation and Penetration Test in Vitro Transdermal Patch Aspirin using a combination of Polymers Eudragit RL 100 and Eudragit Rs 100 with Enhancer variations**

Introduction

Aspirin has been widely used as a medication to prevent secondary heart disease and blood vessels when administered orally. However, this method of administration is not without risks, as it can damage the digestive tract mucosa and potentially cause bleeding. To overcome this problem, researchers have been exploring alternative methods of drug delivery, including the development of transdermal patches. These patches are designed to release a certain dose of medication through the skin, achieving systemic circulation without going through the digestive tract. This study aims to evaluate the combination of Polymers of Eudragit RL 100 and Eudragit RS 100 in aspects of the characteristics and penetration of aspirin from the Transdermal Patch, as well as to assess the effect of adding variations in the penetration enhancer on aspirin penetration.

Background

Transdermal patches have gained popularity in recent years due to their convenience and potential to reduce side effects associated with oral medication. However, the development of effective transdermal patches requires careful consideration of the polymer composition, as it can significantly impact the drug's penetration and release. Eudragit RL 100 and Eudragit RS 100 are two commonly used polymers in transdermal patch formulations, known for their ability to control the release of drugs. This study aims to investigate the combination of these two polymers in the development of transdermal patches for aspirin delivery.

Materials and Methods

This research is experimental and uses the solvent evaporation method for aspirin formulations. Five patch preparations (F1 to F5) were developed with a combination of Eudragit RL 100 and Eudragit Rs 100 in the ratio of 3: 1, 6: 1, 9: 1, 12: 1, and 1: 0. After manufacturing, the penetration test using rabbit skin and Franz diffusion cell devices was conducted to determine the aspirin patch formula with the most effective combination of polymers. Furthermore, twelve additional formulas were made with the addition of penetration enhancers, such as oleic acid, D-limonene, menthol, or polyethylene glycol 400, at a concentration of 5%, 10%, and 15%, with the hope of increasing aspirin penetration into the skin.

Results

The test results show that all patches have good physical characteristics, including transparency, odorless, sticky consistency, and flat surface. The thickness of the patch ranges from 0.134 to 0.137 mm, with a weight between 71,007 to 71.093 mg. In addition, the endurance of this patch is more than 300 folds, and other test results show the development between 4,364 to 5.769%, water vapor content of 1,968 to 3,252%, and water vapor absorption between 1,200 to 2.379%.

Of all the formulas tested, the F5 formula, which only uses the Eudragit RL 100, shows the highest cumulative amount of aspirin, which is 3,156 mg within 8 hours. Meanwhile, for the variation of penetration enhancers, the F5C formula containing 15% oleic acid produces the highest cumulative amount of aspirin, which is 7.569 mg. Incompatibility examination shows there is no significant interaction between aspirin and polymer, which gives confidence in formula stability.

Discussion

Based on the results of this study, it can be concluded that the transdermal patch aspirin shows good physical characteristics and can be a safer alternative to drug administration compared to oral methods. Formula with a combination of Eudragit RL 100 without Eudragit RS 100 (Formula F5) and the addition of 15% oleic acid (Formula F5C) is the most effective combination to increase aspirin penetration into the skin. This finding opens opportunities for the development of other transdermal patch preparations with higher therapeutic potential and lower side effects.

Conclusion

In conclusion, this study demonstrates the potential of transdermal patches as a safer and more effective alternative to oral medication. The combination of Eudragit RL 100 and Eudragit RS 100, along with the addition of penetration enhancers, can significantly improve the penetration of aspirin into the skin. The results of this study provide valuable insights for the development of transdermal patch preparations and highlight the importance of careful consideration of polymer composition and penetration enhancers in the formulation of transdermal patches.

Future Directions

Future studies should focus on optimizing the formulation of transdermal patches to achieve higher therapeutic potential and lower side effects. Additionally, the development of transdermal patches for other medications should be explored to expand the range of applications for this technology. By continuing to advance the field of transdermal patch development, researchers can create safer and more effective alternatives to traditional medication delivery methods.

Limitations

This study has several limitations that should be addressed in future research. Firstly, the use of rabbit skin and Franz diffusion cell devices may not accurately reflect human skin and drug delivery. Secondly, the study only investigated the combination of Eudragit RL 100 and Eudragit RS 100, and other polymer combinations should be explored to determine their potential benefits. Finally, the study only examined the effect of penetration enhancers on aspirin penetration, and other factors, such as drug release and stability, should be investigated in future studies.

Conclusion

Frequently Asked Questions

Q: What is the purpose of this study?

A: The purpose of this study is to evaluate the combination of Polymers of Eudragit RL 100 and Eudragit RS 100 in aspects of the characteristics and penetration of aspirin from the Transdermal Patch, as well as to assess the effect of adding variations in the penetration enhancer on aspirin penetration.

Q: What are the benefits of using transdermal patches compared to oral medication?

A: Transdermal patches have several benefits compared to oral medication, including reduced risk of digestive tract damage, lower risk of bleeding, and improved patient compliance.

Q: What are the key findings of this study?

A: The key findings of this study include the development of five patch preparations with a combination of Eudragit RL 100 and Eudragit Rs 100, and the addition of penetration enhancers to increase aspirin penetration into the skin. The results show that the F5 formula, which only uses the Eudragit RL 100, shows the highest cumulative amount of aspirin, and the F5C formula containing 15% oleic acid produces the highest cumulative amount of aspirin.

Q: What are the limitations of this study?

A: The limitations of this study include the use of rabbit skin and Franz diffusion cell devices, which may not accurately reflect human skin and drug delivery. Additionally, the study only investigated the combination of Eudragit RL 100 and Eudragit RS 100, and other polymer combinations should be explored to determine their potential benefits.

Q: What are the future directions for this research?

A: Future studies should focus on optimizing the formulation of transdermal patches to achieve higher therapeutic potential and lower side effects. Additionally, the development of transdermal patches for other medications should be explored to expand the range of applications for this technology.

Q: What are the potential applications of this research?

A: The potential applications of this research include the development of transdermal patches for other medications, such as pain relief, hormone replacement therapy, and nicotine replacement therapy. Additionally, this research can be used to improve the formulation of existing transdermal patches to achieve higher therapeutic potential and lower side effects.

Q: What are the potential risks associated with transdermal patches?

A: The potential risks associated with transdermal patches include skin irritation, allergic reactions, and the potential for drug accumulation in the skin. However, these risks can be minimized by careful formulation and testing of transdermal patches.

Q: How can this research be used to improve patient care?

A: This research can be used to improve patient care by providing a safer and more effective alternative to oral medication. Transdermal patches can be designed to release medication at a controlled rate, reducing the risk of side effects and improving patient compliance.

Q: What are the next steps for this research?

A: The next steps for this research include further optimization of the formulation of transdermal patches, investigation of other polymer combinations, and exploration of the potential applications of this technology.